Announcements Trials

Browse Landscape

Phase

Status

Unknown 1 Terminated 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Giant Cell Tumor of Bone 2 Breast Neoplasms 2 Thyroid Cancer Metastatic 1 Osteoporotic Fractures 1 Osteoporosis 1 Osteopetrosis, mild autosomal recessive form 1 Osteopetrosis, Autosomal Recessive 7 1 Osteoblastoma 1 Neoplasm Metastasis 1 Musculoskeletal Pain 1 Melanoma 1 Kidney Neoplasms 1 Granuloma, Giant Cell 1 Chondroblastoma 1 Carcinoma, Renal Cell 1 Bone Metastasis From Solid Tumors 1 Bone Metastases From Solid Tumors 1 Bone Metastases 1 Bone Cysts, Aneurysmal 1 Arthralgia 1

Interventions

Sunitinib 14 aldesleukin 10 Bevacizumab 8 pembrolizumab 7 Nivolumab 7 pazopanib 5 Axitinib 5 atezolizumab 4 Interferon-alpha 4 sintilimab 3 durvalumab 3 Sorafenib 3 Everolimus 3 Cyclophosphamide 3 Chemotherapy, Adjuvant 3 toripalimab 2 sargramostim 2 olaparib 2 lenvatinib 2 fludarabine phosphate 2 camrelizumab 2 avelumab 2 Neoadjuvant Therapy 2 Laparoscopy 2 Ipilimumab 2 Interferon alpha-2 2 Immunohistochemistry 2 Immune Checkpoint Inhibitors 2 Gene Expression Profiling 2 Fluorouracil 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Carcinoma, Renal Cell × Denosumab × Clear all

NCT03280667 2023-03-29

KEYPAD

Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Phase 2 Unknown

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡